The estimated Net Worth of Jonathan W Ayers is at least $271 Milión dollars as of 6 May 2024. Mr. Ayers owns over 257 units of Idexx Laboratories stock worth over $130,238,059 and over the last 21 years he sold IDXX stock worth over $132,640,311. In addition, he makes $8,309,800 as Director at Idexx Laboratories.
Jonathan has made over 105 trades of the Idexx Laboratories stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 257 units of IDXX stock worth $125,997 on 6 May 2024.
The largest trade he's ever made was exercising 93,688 units of Idexx Laboratories stock on 31 January 2014 worth over $3,869,314. On average, Jonathan trades about 16,515 units every 30 days since 2003. As of 6 May 2024 he still owns at least 265,651 units of Idexx Laboratories stock.
You can see the complete history of Mr. Ayers stock trades at the bottom of the page.
Jonathan W. Ayers serves as Director of the Company. Mr. Ayers has been the Chairman of the Board, President and Chief Executive Officer of IDEXX since January 2002. Before joining IDEXX, Mr. Ayers held various executive leadership positions at United Technologies Corporation and its business unit Carrier Corporation from 1995 to 2001. Prior to that, Mr. Ayers held various investment banking positions at Morgan Stanley & Co. for nine years. Mr. Ayers holds an undergraduate degree in molecular biophysics and biochemistry from Yale University and graduated from Harvard Business School in 1983 with high distinction. As our President and Chief Executive Officer for more than seventeen years, Mr. Ayers brings outstanding leadership skills, a long-term strategic vision for IDEXX rooted in our Purpose and a deep understanding of IDEXX, our technologies, customers, employees and markets — including our primary market: global pet healthcare. Since his arrival at IDEXX in 2002, we have consistently generated exceptional, above-market returns through continuous innovation. Mr. Ayers also brings significant and diverse experience in many relevant areas, including global business strategy, management, finance, business development, marketing, product development and software technology. In addition, in his role as Chairman of the Board and Chief Executive Officer, he strongly connects the Board with management and enables effective Board oversight that is informed by his broad and deep knowledge of IDEXX and its business.
As the Director of Idexx Laboratories, the total compensation of Jonathan Ayers at Idexx Laboratories is $8,309,800. There are no executives at Idexx Laboratories getting paid more.
Jonathan Ayers is 64, he's been the Director of Idexx Laboratories since 2019. There are 4 older and 21 younger executives at Idexx Laboratories. The oldest executive at Idexx Laboratories, Inc. is M. Anne Szostak, 69, who is the Independent Director.
Jonathan's mailing address filed with the SEC is ONE IDEXX DRIVE, , WESTBROOK, ME, 04092.
Over the last 22 years, insiders at Idexx Laboratories have traded over $238,711,289 worth of Idexx Laboratories stock and bought 24,695 units worth $3,109,424 . The most active insiders traders include Stuart Essig, Johnny D Powers a Jonathan W Ayers. On average, Idexx Laboratories executives and independent directors trade stock every 9 days with the average trade being worth of $4,641,291. The most recent stock trade was executed by M Anne Szostak on 5 September 2024, trading 500 units of IDXX stock currently worth $234,685.
idexx laboratories, inc. (nasdaq: idxx) is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. headquartered in southern maine, idexx conducts operations through more than 70 locations around the world, serves customers in over 175 countries, and employs more than 6,000 people. idexx's primary business focuses on pet health, a growing market around the world. idexx products —in-clinic diagnostic tests and instrumentation, reference laboratory and telemedicine consultation services, and practice management software—enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency and to build more economically successful practices. idexx also develops and manufactures diagnostic tests and information for the global production animal industry, including poultry and livestock, as well as tests for the quality and safety of water an
Idexx Laboratories executives and other stock owners filed with the SEC include: